CTSS and myeloid sarcoma: In this study, we evaluated biomarkers by immunoassays, of tissue destruction, reflected by biglycan degraded by matrix metalloproteinases (MMPs) (BGM), cathepsin S-degraded nidogen (NIC), and MMP-degraded secreted protein acidic and rich in cysteine (SPARC-M) in healthy donors and patients diagnosed with MS.